It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse. Deletion of NRP1 in both CD4+ and CD8+ T cells enhance CD8+ T-cell infiltration into tumours and restricted tumour growth in animal models. Conversely, over-expression of SEMA3A inhibit CD8+ T-cell infiltration. We further show that SEMA3A affects CD8+ T cell F-actin, leading to inhibition of immune synapse formation and motility. Examining a clear cell renal cell carcinoma patient cohort, we find that SEMA3A expression is associated with reduced survival, and that T-cells appear trapped in SEMA3A rich regions. Our study establishes SEMA3A as an inhibitor of effector CD8+ T cell tumour infiltration, suggesting that blocking NRP1 could improve T cell function in tumours.
Interactions between Semaphorin-3A (SEMA3A) and Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 have been shown to affect T cell development. Here the authors investigate how these interactions affect CD8+ T cells in tumour immunity, showing that NRP-1, Plexin-A1 and Plexin-A4 are upregulated on T cells allowing tumour derived SEMA3A to inhibit CD8+ T cell migration and function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




















1 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Southern Denmark, Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Department of Clinical Immunology, Odense University Hospital, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170)
2 University of Oxford, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); CancerCare Manitoba, Paul Albrechtsen Research Institute, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
3 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 University of Oxford, Kennedy Institute of Rheumatology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
6 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Universidade de Lisboa, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Lisbon, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263)
7 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oregon Health and Science University, Pulmonary and Critical Care Medicine, Portland, US (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
8 University of Oxford, Division of Structural Biology, Wellcome Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
9 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Cambridge, Division of Gastroenterology & Hepatology, Department of Medicine, Cambridge University Hospitals, Cambridge, England (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Early Cancer Institute, Department of Oncology, Cambridge, England (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934)
10 Radcliffe Observatory Quarter, Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
11 Ørsteds Plads, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870)
12 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Kennedy Institute of Rheumatology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
13 University of Oxford, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)